Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMRANASDAQ:OVIDNASDAQ:SPPINASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMRAIMARA$51.67+9.5%$17.12$0.97▼$6.32$1.36B1.09138,364 shs6,598 shsOVIDOvid Therapeutics$0.29+2.1%$0.31$0.24▼$3.31$20.29M0.27471,131 shs472,293 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AYMABY-mAbs Therapeutics$4.41+2.1%$4.39$3.55▼$16.11$199.70M0.53311,911 shs181,552 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMRAIMARA0.00%-22.13%-15.15%+646.93%+646.93%OVIDOvid Therapeutics+2.14%+0.55%-16.00%-45.81%-90.29%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%YMABY-mAbs Therapeutics+2.08%+4.26%+7.56%-19.96%-63.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMRAIMARAN/AN/AN/AN/AN/AN/AN/AN/AOVIDOvid Therapeutics4.1771 of 5 stars3.53.00.04.62.02.50.6SPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AYMABY-mAbs Therapeutics3.4813 of 5 stars4.41.00.00.03.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMRAIMARA 0.00N/AN/AN/AOVIDOvid Therapeutics 3.00Buy$2.78855.16% UpsideSPPISpectrum Pharmaceuticals 0.00N/AN/AN/AYMABY-mAbs Therapeutics 2.82Moderate Buy$16.60276.42% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, OVID, SPPI, and IMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025OVIDOvid TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.00 ➝ $1.505/19/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.005/14/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.005/14/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.004/24/2025OVIDOvid TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/22/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.003/24/2025OVIDOvid TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.003/21/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $12.003/12/2025OVIDOvid TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $3.003/5/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $18.003/5/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMRAIMARAN/AN/A$0.69 per share75.24$3.44 per shareN/AOVIDOvid Therapeutics$548K37.81N/AN/A$1.24 per share0.24SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87YMABY-mAbs Therapeutics$88.66M2.25N/AN/A$2.32 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMRAIMARA$1.49M$0.051,033.63∞N/AN/A2.12%2.00%N/AOVIDOvid Therapeutics-$52.34M-$0.35N/AN/AN/A-5,142.56%-39.24%-26.19%8/12/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AYMABY-mAbs Therapeutics-$21.43M-$0.64N/AN/AN/A-28.22%-24.61%-18.49%8/11/2025 (Estimated)Latest YMAB, OVID, SPPI, and IMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025OVIDOvid Therapeutics-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million5/13/2025Q1 2025YMABY-mAbs Therapeutics-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million3/11/2025Q4 2024OVIDOvid Therapeutics-$0.16-$0.13+$0.03-$0.13$0.19 million$0.08 million3/4/2025Q4 2024YMABY-mAbs Therapeutics-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMRAIMARAN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMRAIMARAN/A48.9848.98OVIDOvid Therapeutics0.185.665.66SPPISpectrum PharmaceuticalsN/A2.712.38YMABY-mAbs TherapeuticsN/A3.923.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMRAIMARA49.28%OVIDOvid Therapeutics72.24%SPPISpectrum Pharmaceuticals21.67%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipIMRAIMARA37.30%OVIDOvid Therapeutics13.10%SPPISpectrum Pharmaceuticals2.70%YMABY-mAbs Therapeutics22.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMRAIMARA4126.23 million16.45 millionNot OptionableOVIDOvid Therapeutics6071.11 million61.57 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableYMABY-mAbs Therapeutics15045.28 million34.71 millionOptionableYMAB, OVID, SPPI, and IMRA HeadlinesRecent News About These CompaniesInfinitum Asset Management LLC Purchases New Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 28 at 6:10 AM | marketbeat.comY-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025May 26 at 11:39 PM | insidermonkey.comY-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research MeetingMay 26 at 10:34 AM | quiverquant.comY-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research MeetingMay 26 at 10:00 AM | globenewswire.comY-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdlesMay 24, 2025 | investing.comHC Wainwright Brokers Decrease Earnings Estimates for YMABMay 23, 2025 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for YMABMay 23, 2025 | americanbankingnews.comFY2026 Earnings Forecast for YMAB Issued By HC WainwrightMay 22, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC WainwrightMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 20, 2025 | marketbeat.comHC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $11.00May 20, 2025 | americanbankingnews.comYMAB FY2025 EPS Forecast Raised by Cantor FitzgeraldMay 18, 2025 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $16.70 Consensus Target Price from AnalystsMay 18, 2025 | americanbankingnews.comWedbush Cuts Earnings Estimates for Y-mAbs TherapeuticsMay 17, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from BrokeragesMay 17, 2025 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)May 16, 2025 | theglobeandmail.comParadigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 16, 2025 | marketbeat.comY-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and ChallengesMay 14, 2025 | finance.yahoo.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | finanznachrichten.deY-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsTop 4 ETFs for China Exposure After Tariff Relief By Nathan Reiff | May 17, 2025View Top 4 ETFs for China Exposure After Tariff Relief These ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsBuild a Complete Bond Portfolio With These 4 ETFsBy Nathan Reiff | May 17, 2025View Build a Complete Bond Portfolio With These 4 ETFsYMAB, OVID, SPPI, and IMRA Company DescriptionsIMARA NASDAQ:IMRAIMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Ovid Therapeutics NASDAQ:OVID$0.29 +0.01 (+2.14%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.29 0.00 (-0.14%) As of 05/27/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Y-mAbs Therapeutics NASDAQ:YMAB$4.41 +0.09 (+2.08%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$4.41 0.00 (0.00%) As of 05/27/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.